<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000906</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 401</org_study_id>
    <secondary_id>11357</secondary_id>
    <nct_id>NCT00000906</nct_id>
  </id_info>
  <brief_title>Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients</brief_title>
  <official_title>The Effect of HIV Protease Inhibitors on the Stereospecific Metabolism of Methadone in HIV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe to combine methadone with two HIV protease&#xD;
      inhibitors (PIs), ritonavir (RTV) and saquinavir (SQV), in HIV-infected patients not&#xD;
      currently taking PIs. This study will measure the interactions between methadone and the PIs.&#xD;
&#xD;
      Methadone is used treat addicts and to treat severe pain. In order to find the safest way to&#xD;
      use methadone with PIs, it is important to evaluate how they interact.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methadone is extensively used in the maintenance treatment of addicts and in the management&#xD;
      of severe pain. In order to use methadone with HIV protease inhibitors correctly, it is&#xD;
      important to evaluate and quantify interactions between the protease inhibitors and&#xD;
      methadone.&#xD;
&#xD;
      Patients receive their usual daily dose of methadone followed with ritonavir and saquinavir,&#xD;
      respectively, twice a day. Patients are evaluated on Day 4 for safety and tolerance, and&#xD;
      their ritonavir dose is increased. On Day 8 patients are evaluated for a steady-state level&#xD;
      of methadone. After 2 weeks of the protease inhibitor therapy, they return for methadone&#xD;
      pharmacokinetic sampling at Day 15 over 24 hours. Both protease inhibitors and methadone are&#xD;
      administered on Day 15 on an inpatient basis. On Day 30, patients are assessed for safety and&#xD;
      tolerance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        You may be eligible for this study if you:&#xD;
&#xD;
          -  Are HIV-positive and have an HIV RNA count below 100,000 copies/ml within 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Are taking methadone.&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are within 40% of your ideal body weight and weigh at least 99 lbs.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        You will not be eligible for this study if you:&#xD;
&#xD;
          -  Are allergic to or are unable to take RTV or SQV.&#xD;
&#xD;
          -  Have a history of treatment failure with indinavir, RTV, or SQV.&#xD;
&#xD;
          -  Have a history of certain illnesses that might prevent you from completing the study.&#xD;
&#xD;
          -  Have severe diarrhea or other stomach problems.&#xD;
&#xD;
          -  Have taken any PI within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Would be unable to complete the study due to alcohol or drug abuse.&#xD;
&#xD;
          -  Are co-enrolled in other protocols that have you taking medications that are&#xD;
             prohibited in this study.&#xD;
&#xD;
          -  Are taking PIs other than RTV or SQV.&#xD;
&#xD;
          -  Are receiving certain therapies or are taking certain medications, including&#xD;
             experimental drugs.&#xD;
&#xD;
          -  Have an active opportunistic (AIDS-related) infection or disease that requires&#xD;
             medication within 14 days prior to study entry.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John G. Gerber</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Joseph Gal</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, Gulick R, Hughes V, Flexner C, Aweeka F, Hsu A, Gal J; ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):153-60. doi: 10.1097/00126334-200106010-00010.</citation>
    <PMID>11404537</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methadone</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Adolescent Behavior</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Narcotics</keyword>
  <keyword>Substance-Related Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

